Welcome to our dedicated page for Remegen news (Ticker: REGMY), a resource for investors and traders seeking the latest updates and insights on Remegen stock.
RemeGen Co., Ltd. develops biopharmaceutical products, including antibody-drug conjugates, bispecific antibodies and fusion-protein biologics for autoimmune disease, oncology and ophthalmology. News for REGMY centers on telitacicept (RC18/泰爱®), disitamab vedotin (RC48/爱地希®), RC28-E and RC148, with recurring updates on clinical data, medical-conference presentations, licensing agreements and regulatory decisions.
Company announcements have covered NMPA approvals for telitacicept in China, orphan-drug and IND-related regulatory actions, Phase III autoimmune studies in myasthenia gravis and Sjögren's syndrome, and oncology data in HER2-expressing urothelial, gastric and other solid tumors. RemeGen also reports collaborations that extend development or commercialization rights for selected pipeline assets.
RemeGen announced the inclusion of two innovative drugs, Telitacicept (RC18) for systemic lupus erythematosus and Disitamab Vedotin (RC48) for gastric cancer, in China's National Reimbursement Drug List. This recognition highlights their clinical efficacy and aims to improve patient access to effective treatments. Telitacicept offers a first-in-class approach for SLE, while Disitamab Vedotin targets HER2-expressing gastric cancer. The drugs address critical unmet medical needs and are expected to bolster RemeGen's market presence and business development.